Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New compound holds promise for lupus and related diseases

16.10.2002


A chemical cousin of anti-anxiety medications, such as Valium and Xanax, significantly reduces kidney inflammation in mice inbred to develop a disease resembling human systemic lupus erythematosus (SLE), researchers at the University of Michigan and the University of California-Berkeley have found.



Their research, described in the Oct. 16 issue of the Journal of Clinical Investigation, also reveals the novel mechanism by which the compound works, a discovery that could lead to safer and more effective new drugs for managing lupus and other autoimmune disorders.

"The best available therapies for lupus haven’t changed for many, many years," says U-M’s Gary D. Glick, Ph.D., one of the lead authors on the study. "It’s a disease where the mechanisms that normally prevent the immune system from attacking components of one’s own body are defective. Because we do not yet understand what triggers lupus, it has been very difficult to develop lupus-specific therapies."


In fact, the mainstays of treating lupus-related kidney inflammation---the major cause of illness and death in lupus patients---are drugs developed many years ago to kill cancer cells. When given to lupus patients, often in combination with immune-suppressing steroids, these cytotoxic agents kill immune cells. But because they lack specificity, they also kill healthy cells, resulting in serious side effects. What’s more, they simply are not effective in some patients.

"Our compound, on the other hand, goes in and kills the bad players but leaves the good players alone," says Glick, a charter faculty member of the U-M Life Sciences Institute, who is the Werner E. Bachmann Collegiate Professor of Chemistry, and a professor of biological chemistry in the U-M Medical School.

The compound, a 1,4-benzodiazepine (designated as Bz-423), sets off a chain of events that results in apoptosis, a natural cell-suicide process by which the body rids itself of cells it no longer needs. In autoimmune disorders such as lupus, something interferes with apoptosis, and immune system cells survive and run amok instead of dying on cue. The abnormally surviving immune system cells produce antibodies, which attack the body’s healthy cells and tissues. The result is harmful and sometimes fatal inflammation in various tissues and organs, particularly the kidneys.

According to the Centers for Disease Control and Prevention, lupus affects 1.4 million Americans, and more than 22,000 have died as a result of the disease over the past 20 years. Women of childbearing age are at greatest risk, and African Americans are more likely than Caucasians to develop the disease, says Anthony Opipari, M.D., Ph.D., assistant professor of obstetrics and gynecology and a lead author of the study.

In an attempt to find new drugs for treating lupus, Glick and his co-workers screened a collection of benzodiazepines to identify any that killed immune cells. They chose benzodiazepines because unlike most cytotoxic drugs, these compounds do not damage DNA or interfere with cell metabolism. "We suspected that any benzodiazepines that were capable of killing cells would possess unique modes of action and perhaps be better at targeting disease-causing cells," says Glick.

In a series of experiments using cultured B cells (immune cells that make antibodies), the researchers found that Bz-423 targets a protein inside the cells’ mitochondria. To test the effectiveness of Bz-423, Glick and his team then gave the compound to mice with lupus. At the end of the treatment period, 60% of untreated mice had lupus-related kidney disease, compared to 16% of treated mice. The treated mice showed none of the side effects caused by currently available lupus drugs.

"The results suggest that Bz-423, when administered appropriately, may have a significant therapeutic potential for lupus," says Glick. There is also evidence that Bz-423 may be useful in treating some types of cancer, as well as other autoimmune diseases, and the researchers are actively pursuing these possibilities, according to Opipari.

"This paper illustrates the wonderful opportunities there are for chemists, such as Drs. Glick and Ellman, who are willing to venture beyond the lab and apply their skills to significant problems in human health," says John M. Schwab, a program director at the National Institute of General Medical Sciences, which supported the research. "At the same time, it shows that clinicians and patients can benefit by including a chemical or molecular perspective in thinking about how to combat a complex, life-threatening disease."

Working with a compound that belongs to one of the most well-studied families of drugs---the benzodiazepines---is remarkably helpful in moving Bz-423 into clinical trials, because so much is already known about chemical and pharmacological properties of that group, Glick says. Although Bz-423 is structurally similar to anti-anxiety drugs such as Valium and Xanax, subtle structural differences give it some advantages. For example, Bz-423 does not cause drowsiness or lead to addiction, says Glick.

After completing additional research on Bz-423, Glick plans to apply to the Food and Drug Administration for permission to test the compound in humans. The University of Michigan has applied for several patents on the medical and pharmacological properties of the compound and its molecular target.


In addition to Glick and Opipari, authors of the paper include M.D.-Ph.D. students Neal B. Blatt, Jeffrey J. Bednarski, and Kathryn M. Johnson; Anthony Boitano, doctoral student in chemistry; Roscoe L. Warner, Ph.D., research investigator in pathology; Raymond L. Yung, M.D., Ph.D., assistant professor of internal medicine; Bruce C. Richardson, M.D., Ph.D., professor of internal medicine; Kent J. Johnson, M.D., professor of pathology; and Jonathan A. Ellman and Francesco Leonetti of the University of California-Berkeley. The research was funded by the National Institutes of Health and the U-M Multipurpose Arthritis Center.

Additional Contact:
Nancy Ross-Flanigan, rossflan@umich.edu, (734) 647-1853


Sally Pobojewski | EurekAlert!

More articles from Health and Medicine:

nachricht A promising target for kidney fibrosis
21.04.2017 | Brigham and Women's Hospital

nachricht Stem cell transplants: activating signal paths may protect from graft-versus-host disease
20.04.2017 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

Im Focus: Quantum-physical Model System

Computer-assisted methods aid Heidelberg physicists in reproducing experiment with ultracold atoms

Two researchers at Heidelberg University have developed a model system that enables a better understanding of the processes in a quantum-physical experiment...

Im Focus: Glacier bacteria’s contribution to carbon cycling

Glaciers might seem rather inhospitable environments. However, they are home to a diverse and vibrant microbial community. It’s becoming increasingly clear that they play a bigger role in the carbon cycle than previously thought.

A new study, now published in the journal Nature Geoscience, shows how microbial communities in melting glaciers contribute to the Earth’s carbon cycle, a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

New quantum liquid crystals may play role in future of computers

21.04.2017 | Physics and Astronomy

A promising target for kidney fibrosis

21.04.2017 | Health and Medicine

Light rays from a supernova bent by the curvature of space-time around a galaxy

21.04.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>